AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously announced on June 30, 2017, Avadel Pharmaceuticals plc (the "Company") received shareholder approval for its 2017 Omnibus Incentive Compensation Plan (the "2017 Omnibus Plan"), the complete text of which was set forth as Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2017. In connection with the 2017 Omnibus Plan, the Company has adopted the U.S. Restricted Stock Unit Award Grant Notice and Agreement for restricted stock units to be issued from time to time under the 2017 Omnibus Plan, in the form attached hereto as Exhibit 10.1 which is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
10.1 |
Form of U.S. Restricted Stock Unit Award Grant Notice and Agreement |
AVADEL PHARMACEUTICALS PLC ExhibitEX-10.1 2 ex10_1-form8k12012017.htm EXHIBIT 10.1 Avadel Pharmaceuticals PLC 2017 Omnibus Incentive Compensation Plan U.S. Restricted Stock Unit Award Grant Notice Avadel Pharmaceuticals PLC (the “Company”),…To view the full exhibit click here
